Illumina, Inc. (ILMN) is a Technology stock trading at $186.68 (as of 2026-07-17), with a market capitalization of $28.24B and a trailing P/E of 43.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Illumina provides sequencing and array-based solutions for genetic and genomic analysis, selling instruments and consumables and also offering genotyping and sequencing services, instrument service contracts, and cancer detection testing.
Illumina's profit model is closely tied to sequencing consumables revenue, since a large portion of its revenue comes from sequencing consumables, and it supports high gross margin (66.1%) and positive operating margin (19.2%).
Business quality (Solid): Good headline profitability metrics and clear emphasis on sequencing and consumables. The dataset does not include a clean, official reportable segment breakdown, so segment-level interpretation is limited.
Valuation: At 32× earnings, ILMN trades 47% below the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.
| Price | $186.68 |
| Market Cap | $28.24B |
| P/E Ratio | 43.5 |
| EV / EBITDA | 27.2 |
| Price / Book | 10.55 |
| Price / Sales | 6.61 |
| FCF Yield | 4.7% |
| DCF Value (model) | $40.69 |
| DCF Upside vs Price | -78.2% |
| Revenue (TTM) | $4.34B |
| Net Margin | 19.6% |
| Revenue Growth (YoY) | -0.7% |
| EPS Growth (YoY) | -171.1% |
| FCF Growth (YoY) | 31.3% |
| Altman Z-Score | 5.65 (safe) |
| Stock P/E | 43.5 |
| Sector P/E (Technology) | 34.7 |
| Industry P/E (Measuring & Control Equipment) | 58.9 |
| vs Sector | 25.3% |
| vs Industry | -26.2% |
| Top Institutional Holder | BlackRock, Inc. ($2.34B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Technology |
| Industry | Measuring & Control Equipment |
| CEO | Jacob Thaysen |
| Employees | 8,970 |
| Country | US |
| IPO Date | 2000-07-28 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.